Biomarkers Cancer|Biotechnology Market Research Reports|Biomarkers Market Research Reports

Brand Principles
Angiogenesis Modulators

Market Research Report - ANGIOGENESIS MODULATORS

For list of other market reports click here

(Published by RI Technologies - Jan '08 - No. of pages: 174)

  • Description
  • Free Samples
  • Summary
  • Companies Mentioned
  • Buy Report

This market research report on Angiogenesis Modulators studies the impact of Inhibitors and Stimulators on various diseases. The study focuses on major angiogenesis inhibitors and their role in diseases such as cancer, dermatology, ophthalmology, rheumatology and other angiogenesis based diseases including endometriosis and inflammatory diseases. The emphasis is also given on major angiogenesis stimulators and their role in diseases such as cardiovascular disorders including ischemia, congestive heart failure, coronary artery disease, myocardial infarction and peripheral vascular disease and chronic wound care. The study provides global market analysis for angiogenesis therapeutic products by the above angiogenesis modulators and also by the disease areas such as cancer, cardiovascular disorders and other angiogenesis based diseases. The research study includes estimates and projections for the total global angiogenesis therapeutic products market.

Free Sample Research Report

Download Table of contents

Global market for Angiogenesis therapeutic products is projected to reach about US$ 22 billion by 2012. Angiogenesis is the formation of new capillary blood vessels and plays an important role in several physiological processes such as wound repair, ovulation, embryonic development, and myocardium generation. With angiogenesis inhibitors showing great promise in reducing malignant tumors in rats, the market potential has greatly increased for therapeutic products in disease areas such as cancer, cardiovascular diseases, ophthalmic diseases, skin diseases, rheumatoid arthritis, and other angiogenesis based diseases.

Angiogenesis research has become one of the most interesting fields in biomedical areas. Cancer is the most prominent area for research with maximum number of drugs being targeted in this disease area. The tumors of cancer cannot survive without the existence and development of new blood vessels. This offers an important scope for researchers to restrict the cancer cells from expanding by restricting the formation of new blood vessels. Research on synthetic and natural angiogenesis inhibitors is also underway. The United States is the leading market for angiogenesis therapeutic products followed by Europe and Asia Pacific. Asia Pacific and Latin American markets are emerging markets with leading pharmaceutical companies outsourcing drug development and clinical trials in these developing regions.

Countries Covered:
United States
Europe
Germany
United Kingdom
France
Switzerland
Rest of Europe
Asia-Pacific
Japan
Rest of Asia-Pacific
Latin America
Rest of World
Abbott Laboratories (USA)
Adnexus Therapeutics, Inc. (USA)
Aeterna Zentaris, Inc. (Canada)
Alcon, Inc. (USA)
Amgen, Inc. (USA)
Angiotech Pharmaceuticals, Inc. (Canada)
Ångstrom Pharmaceuticals, Inc. (USA)
Antisoma plc (UK)
Astrazeneca plc (UK)
Bayer Healthcare AG (Germany)
Callisto Pharmaceuticals, Inc. (USA)
Cardium Therapeutics, Inc. (USA)
Celgene Corporation (USA)
Chugai Pharmaceutical Co., Ltd. (Japan)
Collagenex Pharmaceuticals, Inc. (USA)
Corautus Genetics, Inc. (USA)
Eisai, Inc. (USA)
Entremed, Inc. (USA)
F.Hoffmann-La Roche Ltd. (Switzerland)
Genaera Corporation (USA)
Genentech, Inc. (USA)
Genvec, Inc. (USA)
Genzyme Corporation (USA)
Human Genome Sciences, Inc. (USA)
Imclone Systems, Inc. (USA)
Intradigm Corporation (USA)
Merck KGaA (Germany)
Novartis AG (Switzerland)
OSI Pharmaceuticals, Inc. (USA)
Oxigene, Inc. (USA)
Pfizer, Inc. (USA)
Progen Industries Ltd. (Australia)
Sirna Therapeutics, Inc. (USA)
TAP Pharmaceutical Products, Inc. (USA)
UCB SA (Belgium)

Single Site License-US$ 2800

Global Site License-US$ 6000

For those who are intrested to buy the report by chapter:

CHAPTER

TITLE

SHORT DESCRIPTION

PRICE (US$)

I

 Scope and Methodology

Provides information regarding the research methodology, limitations of the study, market measuring units and exchange rates used.
* Will be delivered free with purchase of any of the other chapters mentioned below.

FREE*

II

 Report Synopsis

Synopsis of the report summarizes the global Angiogenesis Modulators market by segment - therapeutic products including inhibitors, stimulators and therapeutic areas covering cancer, cardiovascular and angiogenesis based diseases. Regional markets are analyzed by product segment and brief profiles of major companies by region are included. The chapter provides the market values in US$ for each segment in several geographic regions such as the US, Canada, Europe, Asia-Pacific and rest of the world.

$1000

 

III

 Product / Technology Research

This chapter gives an insight into Angiogenesis Modulators market including definitions, segmentation and applications. It provides market values in US$ (for the period 2005 through 2011) for Angiogenesis Modulators. Angiogenesis in diseases and remedies through stimulators and inhibitors are mentioned in the report. It also includes product trends and potential opportunities.

$800

 

IV

 Market Dynamics

The chapter provides information on global markets for Angiogenesis Therapeutic Products. It includes global market analysis (in US$) by geographic region; analysis of each region by both disease areas and modulators; a brief business profile of major global companies; and a report of corporate activities such as mergers and acquisitions, partnerships, new product developments/launches etc. It also includes market trends, global and US cancer demographics and an industry outlook.

$1200

 

V

 Corporate Directory

This chapter provides a comprehensive region-wise list of 325 companies, CROs and academic institutions that are engaged in Angiogenesis Modulator products and / or services.

$300